Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 2/2016

Ausgabe 2/2016

Inhaltsverzeichnis ( 15 Artikel )

01.04.2016 | PRECLINICAL STUDIES | Ausgabe 2/2016

Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549

Izabella Thaís Silva, Fabiana Cristina Geller, Lara Persich, Sabine Eva Dudek, Karen Luise Lang, Miguel Soriano Balparda Caro, Fernando Javier Durán, Eloir Paulo Schenkel, Stephan Ludwig, Cláudia Maria Oliveira Simões

01.04.2016 | PRECLINICAL STUDIES | Ausgabe 2/2016

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats

Xuhui Bao, Vidyalakshmi Chandramohan, Randall P. Reynolds, John N. Norton, William C. Wetsel, Ramona M. Rodriguiz, Dipendra K. Aryal, Roger E. McLendon, Edward D. Levin, Neil A. Petry, Michael R. Zalutsky, Bruce K. Burnett, Chien-Tsun Kuan, Ira H. Pastan, Darell D. Bigner

01.04.2016 | PRECLINICAL STUDIES | Ausgabe 2/2016

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15

Paula Kinsella, Lisa M. Greene, Sandra A. Bright, Jade K. Pollock, Stefania Butini, Giuseppe Campiani, Sebastian Bauer, D. Clive Williams, Daniela M. Zisterer

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Dustin A. Deming, Ludmila L. Cavalcante, Sam J. Lubner, Daniel L. Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill M. Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin G. Doyle, George Wilding, Austin Duffy, Glenn Liu

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

Elizabeth R. Kessler, S. Gail Eckhardt, Todd M. Pitts, Erica L. Bradshaw-Pierce, Cindy L. O’byrant, Wells A. Messersmith, Sujatha Nallapreddy, Colin Weekes, Jennifer Spratlin, Christopher H. Lieu, Madeleine A. Kane, Sarah Eppers, Elizabeth Freas, Stephen Leong

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016 Open Access

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, Annegret Van der Aa, Giocondo Lorenzon, Florence Namour, Philippe Pujuguet, Sophie Darquenne, Filip Y. F. de Vos, Tom J. Snijders, Emile E. Voest, Jan H. M. Schellens, Martijn P. Lolkema

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016

Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies

Emiliano Calvo, Guru Reddy, Valentina Boni, Lina García-Cañamaque, Tao Song, Jette Tjornelund, Mi Rim Choi, Lee F. Allen

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016 Open Access

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

C. E. Halstenson, T. Shamp, M. A. Gargano, R. M. Walsh, M. L. Patchen

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

Jeffrey R. Infante, David S. Mendelson, Howard A. Burris III, Johanna C. Bendell, Anthony W. Tolcher, Michael S. Gordon, Heidi H. Gillenwater, Shirin Arastu-Kapur, Hansen L. Wong, Kyriakos P. Papadopoulos

01.04.2016 | PHASE I STUDIES | Ausgabe 2/2016

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer

Christos E. Kyriakopoulos, Elisabeth I. Heath, Jens C. Eickhoff, Jill Kolesar, Mulusew Yayehyirad, Thomas Moll, George Wilding, Glenn Liu

01.04.2016 | PHASE II STUDIES | Ausgabe 2/2016

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma

Elaine McWhirter, Ian Quirt, Thomas Gajewski, Gregory Pond, Lisa Wang, June Hui, Amit Oza

01.04.2016 | PHASE II STUDIES | Ausgabe 2/2016

An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer

Andrea Necchi, Salvatore Lo Vullo, Luigi Mariani, Daniele Raggi, Patrizia Giannatempo, Giuseppina Calareso, Elena Togliardi, Flavio Crippa, Nicola Di Genova, Federica Perrone, Maurizio Colecchia, Biagio Paolini, Giuseppe Pelosi, Nicola Nicolai, Giuseppe Procopio, Roberto Salvioni, Filippo G. De Braud

01.04.2016 | PHASE II STUDIES | Ausgabe 2/2016

Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation

Sumati Gupta, Launce Gouw, Jennifer Wright, Sant Chawla, Debbie Pitt, Mark Wade, Ken Boucher, Sunil Sharma

01.04.2016 | SHORT REPORT | Ausgabe 2/2016

Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification

Arnaud Uguen, Pascale Marcorelles, Marc De Braekeleer

01.04.2016 | SHORT REPORT | Ausgabe 2/2016

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Naoya Kanogawa, Tomoko Saito, Tenyu Motoyama, Akinobu Tawada, Fumihiko Kanai, Osamu Yokosuka

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise